CSE’s Barrington Miller is joined by Anthony Durkacz, Interim CEO of FSD Pharma (CSE:HUGE) to discuss the company’s recent history and transition from the cannabis-era to new opportunities in the growing psychedelics space.
Here’s an overview of what Barrington and Anthony discuss in this edition of the “Exchange for Entrepreneurs” podcast:
0:00 – Introducing Anthony Durkacz, Interim CEO of FSD Pharma
5:45 – Working back towards a 1Bn market cap
8:10 – The latest investment in Lucid Psycheceuticals Inc. and treating MS
10:50 – The psychedelics movement
14:13 – Listing on NASDAQ
About FSD Pharma Inc.
FSD Pharma, Inc., is a publicly traded holding company since May 2018.
FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, ultra-micronized palmitoylethanolamide (PEA). Ultra-micro PEA is known to target the CB2 receptors of the endocannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response.
The company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently beings dispensed in Italy and Spain as a prescription based medical food supplement since 2004.
The company received permission from the Food and Drug Administration (FDA) on June 1, 2020 to submit an Investigational New Drug Application (IND) for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.
Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
Learn more about FSD Pharma at FSD Pharma Inc. Subordinate Voting Shares | CSE – Canadian Securities Exchange (thecse.com)